EUCTR2015-000554-38-IT进行中（未招募）1 期
A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in Adult Subjects with Spastic Hemiparesis due to Stroke. -
IPSEN INNOVATIO0 个研究点目标入组 99,999 人开始时间: 2018年2月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 99,999
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of written informed consent prior to any study related procedures.
- •2.Male or female subjects between 18 and 80 years of age, inclusive.
- •3.Subjects with spastic hemiparesis, who had only one clinically defined stroke episode.
- •4.Subjects who are at least 6 months post-stroke.
- •5.Subjects who have a MAS score =2 in the primary targeted muscle group (PTMG) for toxin-naive subjects (never received any
- •Botulinum toxin [BTX] in the affected upper limb) or =3 in the PTMG for toxin nonnaive
- •6.Spasticity angle (X of the Tardieu scale) =10° in the PTMG
- •7.Female subjects of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted
- •method of contraception and must agree to continue use of this method for the duration of the study and for 90 days after
- •participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine
- •device, or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •8.Subjects must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during
- •the study period and willing to return to the clinic for the follow-up evaluation as
- •specified in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Major limitation in the passive ROM (XV1 of the Tardieu scale) at the affected elbow, wrist, and fingers, as defined by:
- •Maximum passive elbow extension <150° (0° corresponding to the
- •minimal stretch of the elbow flexors, which corresponds to a fully flexed
- •elbow position)
- •Maximum passive wrist extension <70° (0° corresponding to the
- •minimal stretch of the wrist flexors, which corresponds to a fully flexed
- •wrist position)
- •Maximum passive finger extension <70° (0° corresponding to the
- •minimal stretch of the extrinsic finger flexors, which corresponds to a
- •formed fist with the second phalanx parallel to the metacarpal)
- •2.Subjects treated with BTX of any type within four months prior to study entry for any condition.
- •3.Subjects who have experienced remote spread of effect of previous treatment with BTX (including generalized muscle
- •4.Subjects likely to be treated with BTX of any type during the course of this study.
- •5.Previous primary or secondary non-response to any BTXs for the targeted condition.
- •6.Previous surgery to treat spasticity of the affected upper limb.
- •7.Previous treatment with phenol and/or alcohol in the affected upper limb at any time before the study.
- •8.Subjects treated or likely to be treated with intrathecal baclofen during the course of the study or during the 4 weeks before
- •study entry.
- •9.Physiotherapy initiated less than 4 weeks before entry or expected to be initiated during the study in the affected upper limb.
- •10.Any medical condition (including severe dysphagia or airway disease) that may increase, in the opinion of the Investigator, the
- •likelihood of Adverse Events related to BTX treatment.
- •11.Major neurological impairment other than spastic paresis (including major proprioceptive ataxia or apraxia on the paretic side)
- •that could negatively impact on the functional performance of the subject.
- •12.Known disease of the neuromuscular junction (such as Lambert Eaton myasthenic syndrome or myasthenia gravis).
- •13.Known sensitivity to BTX or any component of Dysport Solution.
- •14.Infection at the injection site(s).
- •15.Current or planned treatment with any drug that interferes either directly or indirectly with neuromuscular function (e.g.
- •aminoglycosides) within the last 4 weeks prior to study treatment.
- •16.Treatment with a new investigational drug in the 4 weeks prior to enrolment into the study or scheduled to receive such a drug
- •during the study period.
- •17.Any underlying disease (not associated with the stroke) likely to affect upper limb function and/or muscle tone and/or
- •spasticity.
- •18.Is pregnant or lactating. A pregnancy test will be performed at the start of the study for all female subjects of childbearing
- •potential (i.e. not surgically sterile or 2 years postmenopausal).
- •19.Has a history of, or known current, problems with substance or alcohol abuse.
- •20.Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the
- •study, and/or evidence of an uncooperative attitude.
- •21.Has any other medical condition(s) that, in the opinion of the investigator, might jeopardise the subject's safety.
研究者
相似试验
进行中（未招募）
1 期
A phase III, placebo controlled clinical trial to assess efficacy and safety of one dose of Dysport solution in the treatment of upper limb spasticity in adults after strokeEUCTR2015-000554-38-CZIpsen Innovation99,999
进行中（未招募）
1 期
A phase III, placebo controlled clinical trial to assess efficacy and safety of one dose of Dysport solution in the treatment of upper limb spasticity in adults after strokeupper limb spastic hemiparesis due to strokeMedDRA version: 18.0Level: LLTClassification code 10058978Term: Spastic hemiparesisSystem Organ Class: 100000004852EUCTR2015-000554-38-SKIpsen Innovation93
进行中（未招募）
1 期
A phase III, placebo controlled clinical trial to assess efficacy and safety of one dose of Dysport solution in the treatment of upper limb spasticity in adults after strokeEUCTR2015-000554-38-BEIpsen Innovation93
招募中
3 期
Study on Yellow Fever Vaccine developed by Serum Institute of India Pvt. Ltd. for comparison of safety and immunogenicity with other vaccine (STAMARIL) In Healthy InfantsYellow FeverPACTR202206910703861Serum Institute of India Pvt Ltd.2,216
招募中
3 期
Study to Compare Safety and Immunogenicity of Yellow Fever Vaccine of Serum Institute of India with with STAMARIYellow FeverPACTR202206719871582Serum Institute of India Pvt Ltd.1,824